<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00613769</url>
  </required_header>
  <id_info>
    <org_study_id>TSM</org_study_id>
    <secondary_id>EudraCT number 2006-006575-20</secondary_id>
    <nct_id>NCT00613769</nct_id>
  </id_info>
  <brief_title>Orally Administered Trimethoprim-sulfamethoxazole and Metronidazole as Prophylaxis of Infection Following Elective Colorectal Surgery</brief_title>
  <official_title>A Prospective, Randomized, Blind, Multicenter Trial Comparing Orally Administered Trimethoprim-sulfamethoxazole With Intravenously Administered Cefuroxime and Metronidazole as Prophylaxis of Infection Following Elective Colorectal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Halmstad County Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Halmstad County Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current standard Swedish infection prophylaxis in colorectal surgery is intravenously
      administered cefuroxime and metronidazole. this combination is well studied. The
      disadvantages of the regimen is &quot;collateral damage&quot; resulting from treatment with a
      cephalosporine and that the combination also serves as the first line of treatment for
      abdominal surgical infections.

      Serval Swedish surgical departments have for some years used a combination of orally
      administered trimethoprim-sulfamethoxazole and metronidazole.

      The combination is economical and believed to be effective but hitherto the outcome have not
      been properly researched.

      The aim of this study is to compare the efficacy of these two regimens in the prevention of
      infection after elective colorectal surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cutaneous-,subcutaneous and intraabdominal infections</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non infectious wound complications</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications to the anastomosis</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse reaction of given drug</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other post operative infections</measure>
    <time_frame>During hospital stay</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Septicaemia</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1073</enrollment>
  <condition>Infection Prophylaxis in Colo Rectal Surgery</condition>
  <arm_group>
    <arm_group_label>ordinary per operative prophylaxis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cefuroxime(1500mg) i.v.+ metronidazole (1500mg)i.v.given at the time point of induction of anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Per oral alternative</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trimethoprim-sulfamethoxazole(160mg/800mg)p.o.+metronidazole (1200mg)p.o.given 06.00 am on the day of operation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trimethoprim-sulfamethoxazole + metronidazole</intervention_name>
    <description>trimethoprim-sulfamethoxazole (160mg/800mg)p.o.+ metronidazole (1200mg)p.o.</description>
    <arm_group_label>Per oral alternative</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cefuroxime and metronidazole</intervention_name>
    <description>cefuromime 1500mg i.v. + metronidazole 1500mg i.v.</description>
    <arm_group_label>ordinary per operative prophylaxis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;= 18 years

          -  Planned clean/clean-contaminated colorectal resection will be performed

          -  Understand spoken and written swedish language

        Exclusion Criteria:

          -  Hypersensibility to the test or control drug

          -  Severe liver failure

          -  Blood dyscrasia

          -  Ileus or gastric retention

          -  Current visceral perforation

          -  Current treatment with antibiotics

          -  Current treatment with steroids

          -  Cytotoxic or radiation therapy within 4 weeks of the planned operation

          -  Active IBD (inflammatory bowel disease)

          -  Incapability to swallow tablets

          -  Other study interfering with this study

          -  Current pregnancy

          -  Bad regulated diabetes

          -  Current enterocutaneous or colocutaneous fistula
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claes Hjalmarsson, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Surgery and Oncology, Halland Hospital Halmstad, 301 85 Halmstad, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Surgery, University hospital Sahlgrenska/Östra</name>
      <address>
        <city>Gothenburg</city>
        <zip>416 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Surgery and oncology, Halland Hospital in Halmstad</name>
      <address>
        <city>Halmstad</city>
        <zip>301 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of surgery, Community Hospital i Karlskrona</name>
      <address>
        <city>Karlskrona</city>
        <zip>371 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vrinnevi hospital</name>
      <address>
        <city>Norrköping</city>
        <zip>601 82</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of surgery</name>
      <address>
        <city>Skövde</city>
        <zip>541 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Surgery, NU-hospitals</name>
      <address>
        <city>Uddevalla</city>
        <zip>451 80</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2008</study_first_submitted>
  <study_first_submitted_qc>January 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2008</study_first_posted>
  <last_update_submitted>September 27, 2012</last_update_submitted>
  <last_update_submitted_qc>September 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Halmstad County Hospital</investigator_affiliation>
    <investigator_full_name>Claes Hjalmarsson</investigator_full_name>
    <investigator_title>MDPhD</investigator_title>
  </responsible_party>
  <keyword>Surgical site infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cefuroxime axetil</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
    <mesh_term>Cefuroxime</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

